Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesGastroenterologycareoregon Mesalamine Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentcareoregonPolicy N/A

    Mesalamine prior authorization guideline

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization guideline for mesalamine products (generic mesalamine and Pentasa) for Crohn's disease and ulcerative colitis; defines coverage criteria, step therapy, documentation, and approval length.

    Policy Summary
    Payercareoregon
    PolicyMesalamine prior authorization guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document failure or intolerance to sulfasalazine or balsalazide (and for Pentasa, prior failure of generic oral mesalamine or Apriso or provider justification).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-07-01policy effective date
    2 productscovered products named
    2 indicationsnamed diagnoses
    Lifetimeapproval length

    Coverage Criteria for Mesalamine (generic and Pentasa)

    Policy Summary
    Payercareoregon
    PolicyMesalamine prior authorization guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document failure or intolerance to sulfasalazine or balsalazide (and for Pentasa, prior failure of generic oral mesalamine or Apriso or provider justification).
    SourceLink
    On This Page
    Coverage Criteria for Mesalamine (generic and Pentasa)Provider Requirements and Authorization ActionsDefinitions and Operational NotesBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Mesalamine (generic and Pentasa) initial authorization criteria

    Covered when ALL of the following are met

    Primary indication: Diagnosis of Crohn's disease
    Step therapy: Member has failed or is intolerant to ONE of the following: sulfasalazine OR balsalazide

    Documentation of poor disease control from non-compliance with multi-day dosing will qualify, but an adequate trial must first be tried

    Pentasa-specific: For Pentasa, either (A) failed a generic oral mesalamine product OR Apriso, OR (B) provider states full GI tract involvement requires Pentasa release mechanism

    Ulcerative colitis — small bowel activity

    Covered when ALL of the following are met

    Ulcerative colitis with small bowel involvement: Diagnosis of Ulcerative colitis AND disease is described as active in the small bowel (proximal to the colon)

    No other diagnoses or indications are listed as covered in this guideline beyond those specified in the approval criteria. The policy specifies coverage only for the named inflammatory bowel disease indications and related criteria.

    Requests that do not document the required prior failure or intolerance to the listed alternatives (sulfasalazine or balsalazide), or that do not meet the Pentasa-specific requirements (failure of a generic oral mesalamine product or Apriso, or other documented justification), are not supported by the approval criteria in this document and may be denied.

    Provider Requirements and Authorization Actions

    Prior Authorization

    Prior authorization required; lifetime approval length

    Prior authorization is required for Generic mesalamine and Pentasa. Approval length is lifetime through 12/31/2039.

    Step Therapy

    Step therapy — required failures before approval

    Member must have failed or be intolerant to ONE of the following before approval: sulfasalazine or balsalazide. For Pentasa specifically, the member must have failed a generic oral mesalamine product or Apriso, unless the provider documents that full GI tract involvement requires Pentasa’s release mechanism.

    • Step requirement: failure or intolerance to sulfasalazine OR balsalazide
    • Pentasa-specific: failed a generic oral mesalamine product OR Apriso, or provider attestation of need for Pentasa release mechanism
    Documentation Required

    Required supporting documentation

    Provide documentation showing the member failed or was intolerant to one of the listed alternatives (sulfasalazine or balsalazide). For Pentasa requests, include documentation of failure of a generic oral mesalamine product or Apriso, or a provider statement that full GI tract involvement requires Pentasa’s release mechanism. Documentation that poor disease control was due to non‑compliance with multi‑day dosing may qualify only after an adequate trial has been attempted.

    • Evidence of prior trial and failure or intolerance to sulfasalazine or balsalazide
    • For Pentasa: record of failure of generic oral mesalamine or Apriso, or provider attestation re: full GI tract involvement
    • If poor control due to non‑adherence is cited, document that an adequate trial was first attempted
    Denial Risk

    Denial risk if diagnosis or prior failure/intolerance not documented

    Requests missing documentation of the covered diagnosis (Crohn’s disease or ulcerative colitis) or lacking proof of prior failure or intolerance to the required agents may be denied.

    • Missing diagnosis documentation (Crohn’s disease or ulcerative colitis) risks denial
    • No documentation of failure/intolerance to required step agents risks denial

    Definitions and Operational Notes

    Failed or intolerant to listed agent
    DefinitionFailure: inadequate therapeutic response after an adequate trial of the listed agent (sulfasalazine or balsalazide).
    DefinitionIntolerance: development of adverse effects or safety concerns that prevent continued use of the listed agent.
    Documentation noteDocumentation that poor disease control due to non‑compliance with multi‑day dosing may qualify as failure, but an adequate trial must first be attempted.
    Full GI tract involvement justification
    RequirementProvider must state that full gastrointestinal tract involvement requires Pentasa’s release mechanism to justify Pentasa use.
    Alternative documentationIf provider does not attest to full GI tract involvement, prior authorization requires documented failure of a generic oral mesalamine product or Apriso before Pentasa is approved.
    ApplicabilityThis attestation applies specifically to Pentasa requests as an alternative to step requirement of failing generic oral mesalamine or Apriso.

    Background

    Mesalamine formulations, including Pentasa and generic mesalamine, are used in the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. This guideline establishes prior authorization and step therapy requirements specific to these products and indications.